MedPath

Exercise Prehabilitation for Locoregional Esophageal Cancer

Not Applicable
Recruiting
Conditions
Esophageal Cancer
Interventions
Behavioral: Exercise
Registration Number
NCT06430346
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Brief Summary

The purpose of the study is to examine the feasibility and acceptability of exercise "prehabilitation" for patients preparing for esophageal cancer resection (removal).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Biopsy-proven locoregional esophageal cancer (LEC)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Treatment plan including neoadjuvant chemoradiation therapy and surgical resection
  • Ability to read and speak English
Exclusion Criteria
  • Regular engagement in resistance training (2x/week targeting all major muscle groups)
  • Screen failure for exercise safety based on PAR-Q
  • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease
  • Recent fracture or acute musculoskeletal injury that precludes ability to participate in resistance training safely
  • Numeric pain rating scale of 7 or more out of 10
  • Myopathic or rheumatologic disease that impacts physical function

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Exercise prehabilitationExerciseIn this trial participants will participate in an exercise program for 5 to 17 weeks, varying with treatment plans. Participants will receive resistance training equipment and participate in resistance training sessions twice per week (approximately 30-45 minutes per session). A Fitbit device will be provided to monitor step counts.
Primary Outcome Measures
NameTimeMethod
RetentionUp to 11 weeks

The number of participants who complete T0 and T1 measures.

Secondary Outcome Measures
NameTimeMethod
Exploratory outcomes and changesUp to 17 weeks

The number of participants who demonstrate improvements in exploratory outcome measures.

Clinical and treatment outcomesUp to 17 weeks

Chi-square testing will be used to determine if there's a difference in perioperative outcomes between groups.

Trial Locations

Locations (1)

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath